RHOJ and melanoma: Initially, we selected 68 promising compounds and experimentally tested their half maximal inhibitory concentrations (IC50s) in SKMel28 melanoma cells—a cell line that we previously determined was sensitive to RHOJ depletion (Figure 2A) (Ho et al., 2012).